MiMedx GroupMDXG +1.15%57 Buyback Yield % is 0.44 as of Jul. 03, 2026, which is at its 10-year median of 0.44. GuruFocus rates MDXG with a GF Score™ of 57/100 and a GF Value™ of $6.90 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 744 Biotechnology companies, MiMedx Group ranks better than 91.13% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for MiMedx Group's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MDXG vs MNPR, FTH, BBOT: Buyback Yield % Comparison
For the Biotechnology subindustry, MiMedx Group's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MiMedx Group Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MiMedx Group's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where MiMedx Group's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MiMedx Group (MDXG) has a Buyback Yield % of 0.44 as of Jul. 03, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on MiMedx Group and its competitors. This is near median its historical median of 0.44. Over the past decade, MiMedx Group's Buyback Yield % has ranged from 0.18 to 9.42. According to the industry distribution chart, MiMedx Group ranks #66 out of 744 companies in the Biotechnology industry, placing it in the top 8.9%.
Is MiMedx Group's Buyback Yield % too high?
MiMedx Group's current Buyback Yield % of 0.44 is near median its 10-year median of 0.44. Over the past 10 years, this metric has ranged from a low of 0.18 to a high of 9.42. Based on the distribution chart, MiMedx Group ranks #66 out of 744 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, MiMedx Group has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does MiMedx Group's Buyback Yield % compare to MNPR and FTH?
According to the Biotechnology industry distribution chart, MiMedx Group ranks #66 out of 744 companies for Buyback Yield %. This places MiMedx Group in the top 9% of its industry — outperforming the majority of peers. Historically, MiMedx Group's own Buyback Yield % has ranged from 0.18 to 9.42 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on MiMedx Group and its competitors. MiMedx Group's current Buyback Yield % is 0.44, which is near median its own 10-year median of 0.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MiMedx Group stock overvalued right now?
Based on GuruFocus' analysis, MiMedx Group (MDXG) is currently considered Significantly Undervalued. The stock's GF Value™ is $6.90, compared to a current price of $3.95 — trading 42.8% below its estimated fair value. The current Buyback Yield % is 0.44, which is near median its 10-year median of 0.44. MiMedx Group's overall GF Score™ is 57/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For MiMedx Group (MDXG), the current Buyback Yield % is 0.44 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MiMedx Group (MDXG) Overvalued in 2026?
Based on GuruFocus' analysis, MiMedx Group stock appears to be undervalued.
The current stock price of $3.95 is trading 42.8% below its estimated GF Value™ of $6.90.
GuruFocus considers MiMedx Group to be Significantly Undervalued.
Key valuation signals for MDXG:
Buyback Yield %: 0.44 (near median its 10-year median of 0.44)
GF Value™: $6.90 vs. price of $3.95 (42.8% below fair value)
No single metric tells the full story. See the MDXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
57GF Score
Get the complete analysis for MDXG
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDXG has been successfully added to your 
